While only a minority of our patient population received FLT3 inhibitors, and although subsequently restricted by patient numbers, outcomes tended to improve in ELN2022 intermediate risk in a subanalysis of AML patients treated in the era of new drugs or within the verum arm of a trial testing an FLT3 inhibitor (Supplementary Fig. S9). Here, FLT3 is linked to acute myeloid leukemia.